Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

Pixium Vision SA

Pixium Vision SA is involved in clinical trials related to late-stage macular degeneration. Self-described assets have been acquired by Science Corporation.

msh id	COM:PIXIUM-VISION
symbol	ALPIX
name	Pixium Vision SA
homepage url	https://www.pixium-vision.com
country	FR
sector	Healthcare
industry	Medical - Instruments & Supplies
market	STOCKS
employee count	40
crunchbase url	-
linkedin url	-
founders	-

market cap	1.25M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.07
growth cost of revenue	-
growth depreciation and amortization	2.57
growth ebitda	-0.03
growth ebitda ratio	-442.89
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.37
growth gross profit	-1
growth gross profit ratio	-

ALPI

COM:PIXIUM-VISION

Pixium Vision SA

Last Close

0.42

30/01 16:35

Market Cap

1.16M

Beta: -

Volume Today

86.01K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	12.9M
cost of revenue	12.9M
depreciation and amortization	2.11M
ebitda	-10.79M
ebitda ratio	-5K
eps	-0.22
eps diluted	-0.22
operating expenses	12.9M
operating income	-12.9M
operating income ratio	-5.97K

accounts receivables	-234.28K
capital expenditure	-99.33K
cash at beginning of period	15.66M
cash at end of period	8.3M
inventory	-
working capital ttm	1.65M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-